Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from ZyVersa Therapeutics ( (ZVSA) ).
On July 25, 2025, ZyVersa Therapeutics, Inc. announced that its common stock has been approved for quotation on the OTCQB Venture Market by the OTC Markets Group. Trading is expected to begin on July 28, 2025, under the symbol ‘ZVSA.’ This development marks a significant step for ZyVersa Therapeutics, potentially enhancing its visibility and accessibility in the financial markets, which could have implications for its stakeholders.
The most recent analyst rating on (ZVSA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on ZyVersa Therapeutics stock, see the ZVSA Stock Forecast page.
Spark’s Take on ZVSA Stock
According to Spark, TipRanks’ AI Analyst, ZVSA is a Underperform.
ZyVersa Therapeutics faces significant financial challenges with no revenue and ongoing losses. Technical indicators show bearish momentum, and the negative P/E ratio suggests overvaluation concerns. The lack of dividend yield further limits investment appeal.
To see Spark’s full report on ZVSA stock, click here.
More about ZyVersa Therapeutics
Average Trading Volume: 5,762,746
Technical Sentiment Signal: Sell
Current Market Cap: $2.14M
For detailed information about ZVSA stock, go to TipRanks’ Stock Analysis page.